J9353 Injection. margetuximab-cmkb, 5 milligrams
Also known as: margetuximab, Margenza
Injection of margetuximab-cmkb, 5 milligram. An engineered human epidermal growth factor receptor 2 monoclonal antibody.
In Plain Language
breast cancer injection; HER2 targeted therapy
Clinical Context
Used for HER2-positive metastatic breast cancer with other chemotherapy. Enhanced Fc region for improved antibody-dependent cellular cytotoxicity.
RVU Information
CPT J9353 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J9353?
CPT J9353 (Injection. margetuximab-cmkb, 5 milligrams) is a J Codes (Drugs) code. Injection of margetuximab-cmkb, 5 milligram. An engineered human epidermal growth factor receptor 2 monoclonal antibody.
How is J9353 administered?
CPT J9353 is administered by a healthcare provider, typically via injection or infusion. Used for HER2-positive metastatic breast cancer with other chemotherapy. Enhanced Fc region for improved antibody-dependent cellular cytotoxicity. It is used by Oncology, Surgery, Internal Medicine.
When is CPT J9353 used?
Used for HER2-positive metastatic breast cancer with other chemotherapy. Enhanced Fc region for improved antibody-dependent cellular cytotoxicity.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.